A review of cancer immunotherapy toxicity.
Kennedy LB, Salama AKS.
CA Cancer J Clin. 2020 Mar;70(2):86-104. doi: 10.3322/caac.21596. Epub 2020 Jan 16.
Integrative Approaches to Cancer Immunotherapy.
Szeto GL, Finley SD.
Trends Cancer. 2019 Jul;5(7):400-410. doi: 10.1016/j.trecan.2019.05.010.
Dynamics and specificities of T cells in cancer immunotherapy.
Oliveira G, Wu CJ.
Nat Rev Cancer. 2023 May;23(5):295-316. doi: 10.1038/s41568-023-00560-y. Epub 2023 Apr 12.
TIGIT in cancer immunotherapy.
Chauvin JM, Zarour HM.
J Immunother Cancer. 2020 Sep;8(2):e000957. doi: 10.1136/jitc-2020-000957.
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.
Isser A, Livingston NK, Schneck JP.
Biomaterials. 2021 Jan;268:120584. doi: 10.1016/j.biomaterials.2020.120584. Epub 2020 Dec 5.
Cancer immunotherapy.
Gajewski TF.
Mol Oncol. 2012 Apr;6(2):242-50. doi: 10.1016/j.molonc.2012.01.002. Epub 2012 Jan 8.
Cancer immunotherapy.
Bergman PJ.
Top Companion Anim Med. 2009 Aug;24(3):130-6. doi: 10.1053/j.tcam.2009.06.001.
Biophysical and mechanobiological considerations for T-cell-based immunotherapy.
Zhuang C, Gould JE, Enninful A, Shao S, Mak M.
Trends Pharmacol Sci. 2023 Jun;44(6):366-378. doi: 10.1016/j.tips.2023.03.007.
Immunotherapy in multiple myeloma.
Jadoon Y, Siddiqui MA.
Cancer Treat Res Commun. 2021;29:100468. doi: 10.1016/j.ctarc.2021.100468. Epub 2021 Oct 2.
Immunotherapy for melanoma.
Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff CL Jr.
Cancer Control. 2002 Jan-Feb;9(1):22-30. doi: 10.1177/107327480200900104.
